Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes?
MA Nauck, JJ Meier - European journal of endocrinology, 2019 - academic.oup.com
GLP-1, a peptide hormone secreted from the gut, stimulating insulin and suppressing
glucagon secretion was identified as a parent compound for novel treatments of diabetes …
glucagon secretion was identified as a parent compound for novel treatments of diabetes …
[HTML][HTML] Titratable fixed-ratio combination of insulin glargine plus lixisenatide: a simplified approach to glycemic control in type 2 diabetes mellitus
F Giorgino, I Caruso, R Napoli - diabetes research and clinical practice, 2020 - Elsevier
Approximately 50% of patients with type 2 diabetes mellitus (T2DM) do not achieve glycemic
targets and require treatment intensification. A fixed-ratio combination of a glucagon-like …
targets and require treatment intensification. A fixed-ratio combination of a glucagon-like …
Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: an adjusted indirect treatment comparison
K Vadher, H Patel, R Mody, JA Levine… - Diabetes, Obesity …, 2022 - Wiley Online Library
Aim To conduct an adjusted indirect treatment comparison (aITC) of the efficacy of
tirzepatide 5/10/15 mg versus semaglutide 2 mg in patients with type 2 diabetes. Materials …
tirzepatide 5/10/15 mg versus semaglutide 2 mg in patients with type 2 diabetes. Materials …
Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and …
Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the
endogenous GLP-1 incretin hormone, improving glycaemic control in type 2 diabetes …
endogenous GLP-1 incretin hormone, improving glycaemic control in type 2 diabetes …
Optimizing fixed-ratio combination therapy in type 2 diabetes
L Perreault, H Rodbard, V Valentine, E Johnson - Advances in Therapy, 2019 - Springer
The progressive nature of type 2 diabetes (T2D) means that many patients will require basal
insulin therapy at some point in the course of the disease due to β-cell failure. As basal …
insulin therapy at some point in the course of the disease due to β-cell failure. As basal …
Titratable fixed‐ratio combination of basal insulin plus a glucagon‐like peptide‐1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes
F Gomez‐Peralta, E Al‐Ozairi, EB Jude… - Diabetes, Obesity …, 2021 - Wiley Online Library
Despite novel therapeutic options, many people with type 2 diabetes (T2D) do not achieve
their HbA1c targets. Given the progressive nature of T2D, many individuals not controlled …
their HbA1c targets. Given the progressive nature of T2D, many individuals not controlled …
An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
Aim To compare the effects of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg on
HbA1c and body weight in patients with type 2 diabetes. Materials and Methods A Bucher …
HbA1c and body weight in patients with type 2 diabetes. Materials and Methods A Bucher …
Efficacy and safety of fixed‐ratio combination insulin degludec/liraglutide in type 2 diabetes: A systematic review and meta‐analysis of randomised controlled trials
R Wang, S Luo, Z Xiao, Z Zhou - … /Metabolism Research and …, 2024 - Wiley Online Library
Background The efficacy and safety of fixed‐ratio combination insulin degludec/liraglutide
(IDegLira) for type 2 diabetes (T2DM) were extensively investigated by the global DUAL …
(IDegLira) for type 2 diabetes (T2DM) were extensively investigated by the global DUAL …
Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study
Background IDegLira is a fixed-ratio combination of insulin degludec and liraglutide with
proven efficacy against simpler regimens and non-inferiority against basal-bolus insulin …
proven efficacy against simpler regimens and non-inferiority against basal-bolus insulin …
The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials
We provided an updated systematic review with meta-analysis of randomized controlled
trials (RCTs) assessing the metabolic effects of combination therapy of insulin and GLP-1RA …
trials (RCTs) assessing the metabolic effects of combination therapy of insulin and GLP-1RA …